See more : Sumitomo Realty & Development Co., Ltd. (8830.T) Income Statement Analysis – Financial Results
Complete financial analysis of Omega Therapeutics, Inc. (OMGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omega Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DongFeng Automobile Co. LTD (600006.SS) Income Statement Analysis – Financial Results
- Bowim S.A. (BOW.WA) Income Statement Analysis – Financial Results
- Klépierre (KLPEF) Income Statement Analysis – Financial Results
- China Resources Cement Holdings Limited (CJRCF) Income Statement Analysis – Financial Results
- Sound Energy plc (SNEGF) Income Statement Analysis – Financial Results
Omega Therapeutics, Inc. (OMGA)
About Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.09M | 2.07M | 144.00K | 0.00 | 0.00 |
| Cost of Revenue | 65.87M | 5.19M | 1.39M | 1.15M | 794.00K |
| Gross Profit | -62.78M | -3.12M | -1.24M | -1.15M | -794.00K |
| Gross Profit Ratio | -2,028.93% | -150.36% | -863.19% | 0.00% | 0.00% |
| Research & Development | 77.17M | 80.00M | 47.87M | 21.06M | 11.93M |
| General & Administrative | 26.19M | 21.82M | 16.60M | 6.24M | 4.23M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.19M | 21.82M | 16.60M | 6.24M | 4.23M |
| Other Expenses | 0.00 | 3.02M | 1.71M | 1.35M | 1.18M |
| Operating Expenses | 103.36M | 104.84M | 66.18M | 28.65M | 17.34M |
| Cost & Expenses | 103.36M | 104.84M | 66.18M | 28.65M | 17.34M |
| Interest Income | 2.81M | 222.00K | 910.00K | 777.00K | 595.00K |
| Interest Expense | 0.00 | 222.00K | 910.00K | 777.00K | 595.00K |
| Depreciation & Amortization | 6.77M | 5.19M | 1.39M | 1.15M | 794.00K |
| EBITDA | -93.49M | -97.58M | -64.64M | -27.50M | -16.55M |
| EBITDA Ratio | -3,021.65% | -4,957.36% | -44,911.81% | 0.00% | 0.00% |
| Operating Income | -100.26M | -102.77M | -66.03M | -28.65M | -17.34M |
| Operating Income Ratio | -3,240.50% | -4,957.36% | -45,855.56% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.83M | 65.00K | -2.25M | -802.00K | -606.00K |
| Income Before Tax | -97.43M | -102.70M | -68.28M | -29.45M | -17.95M |
| Income Before Tax Ratio | -3,148.93% | -4,954.22% | -47,416.67% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -65.00K | 882.00K | 752.00K | 584.00K |
| Net Income | -97.43M | -102.64M | -69.16M | -30.20M | -18.53M |
| Net Income Ratio | -3,148.93% | -4,951.09% | -48,029.17% | 0.00% | 0.00% |
| EPS | -1.80 | -2.14 | -1.45 | -0.63 | -0.39 |
| EPS Diluted | -1.80 | -2.14 | -1.45 | -0.63 | -0.39 |
| Weighted Avg Shares Out | 54.01M | 47.88M | 47.79M | 47.84M | 47.84M |
| Weighted Avg Shares Out (Dil) | 54.01M | 47.88M | 47.79M | 47.84M | 47.84M |
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property
Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
Omega Pacific Earns 51% Interest in Williams Property
Omega Pacific Adds John Williamson as Independent Director
Omega Pacific Extends Historical Hole WM22-02 Mineralization to 2.16 G/t Au Over 96.92 Metres
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
Source: https://incomestatements.info
Category: Stock Reports